Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Athersys (DE:4LS)
FRANKFURT:4LS
Athersys (4LS) Stock News & Sentiment
0 Followers
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Athersys (ATHX – Research Report), Galapagos (GLPG – Research Report) and Beam Therapeutics (BEAM – Research Report).
Athersys (ATHX)
Needham analyst Chad Messer maintained a Buy rating on Athersys today and set a price target of $5.00. The company’s shares closed last Tuesday at $1.65.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 8.3% and a 42.9% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics.
Athersys has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See today’s analyst top recommended stocks >>
Galapagos (GLPG)
Maxim Group analyst Jason McCarthy maintained a Hold rating on Galapagos yesterday. The company’s shares closed last Tuesday at $59.01, close to its 52-week low of $56.79.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 22.4% and a 34.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Galapagos with a $80.67 average price target, which is a 35.7% upside from current levels. In a report issued on August 6, Deutsche Bank also downgraded the stock to Hold with a EUR50.00 price target.
Beam Therapeutics (BEAM)
William Blair analyst Raju Prasad maintained a Buy rating on Beam Therapeutics today. The company’s shares closed last Tuesday at $103.50.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 11.3% and a 49.1% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.
Beam Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $99.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ATHX:
Needham Remains a Buy on Equifax (EFX)
Dicerna Q2 Results Miss Estimates; Shares Slip 12.6%
H.C. Wainwright Keeps a Buy Rating on Fulcrum Therapeutics (FULC)
BTIG Sticks to Its Buy Rating for Castle Biosciences (CSTL)
RealReal (REAL) Gets a Hold Rating from BTIG
...Read more
4LS News on the Web
Investors Observer
Neutral
Investors Observer
Neutral
Investors Observer
Neutral
American City Business Journals
Neutral
InvestorPlace
Neutral
Investors Observer
Neutral
Investors Observer
Neutral
Investing.com
Bearish
News Score - Last 7 Days
Media Buzz
This Week7 articles
Weekly Average6 articles
News Sentiment
This Week50%
Sector Average58%
See how Bullish or Bearish a stock is based on its recent media coverage.
This score is generated using a formula that combines Media Buzz and News Sentiment.
This score is generated using a formula that combines Media Buzz and News Sentiment.
Media Coverage Analysis
The historical news coverage of this asset in the last three months.
FAQ
What is DE:4LS’s Media Buzz Sentiment?
7 articles about DE:4LS were published this week. In an average week, 6 articles are published.
What is DE:4LS’s weekly average amount of articles?
In an average week, 6 articles about DE:4LS are published.
What is DE:4LS’s News Sentiment?
50% of articles about DE:4LS were positive this week, compared to its sector average of 58%.